Beijing Mabworks Biotech Co., Ltd.
Clinical trials sponsored by Beijing Mabworks Biotech Co., Ltd., explained in plain language.
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests a new drug called MIL62 in people with systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. About 316 adults with active lupus will receive either MIL62 or a placebo, and researc…
Phase: PHASE3 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 11:33 UTC
-
New antibody drug aims to control kidney disease
Disease control Recruiting nowThis study tests a new drug called MIL116 in healthy people and those with IgA nephropathy, a kidney disease. The goal is to see if it is safe and can help control the disease by reducing harmful proteins. About 130 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC